CD105 antibody | SN6
AlexaFlour®488 conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557A488) used to evaluate endoglin expression on equine, tendon derived stem/progenitor cells by flow cytometry.
Image caption:
Flow cytometry analysis of cell surface markers CD90, CD73, and CD105 on tendon‐derived stem/progenitor cells isolated by differential adhesion onto substrates precoated with 20 μg/ml fibronectin (f‐TSPCs) and grown in normoxia and 5% hypoxia. A–C: f‐TSPCs (age 1 year) grown in 21% oxygen and incubated with control or antibodies (+) to CD90 (A), CD73 (B), or CD105 (C) for flow cytometry. D–F: f‐TSPCs grown in 5% oxygen and incubated with control or antibodies (+) to CD90 (D), CD73 (E), or CD105 (F) for flow cytometry. a p = 0.024, b p = 0.04, c p = 0.038.
From: Williamson KA, Lee KJ, Humphreys WJ, Comerford EJ, Clegg PD, Canty-Laird EG.
Restricted differentiation potential of progenitor cell populations obtained from the equine superficial digital flexor tendon (SDFT).
J Orthop Res. 2015 Jun;33(6):849-58.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for flow cytometry.
Image caption:
Endothelial adherence of blood monocytes. PBMCs were isolated from HLA-A2+ donors and incubated with HLA-A2− HUVECs (1×106 cells/well) for 2 h, after which the non-adherent PBMCs were removed by washing. The co-cultured cell layers were immediately analysed with dual-colour flow cytometry for HLA-A2 and (A) CD34, (B) CD14, (C) CD11b, (D) CD16, (E) CD105 and (F) CD144 expression. Representative plots from 4–6 individual experiments are shown. (G) Two parameters dot plot showing typical isotype controls.
From: Tso C, Rye K-A, Barter P (2012)
Phenotypic and Functional Changes in Blood Monocytes Following Adherence to Endothelium.
PLoS ONE 7(5): e37091.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for flow cytometry.
Image caption:
Phenotype change from HLA-A2+/CD11b+/CD105− to HLA-A2+/CD11b−/CD105+ on endothelium-adherent blood monocyte-derived cells with increase in size and granularity during co-culture. HLA-A2+ PBMCs (1×106 cells/well) were incubated for 2 h (Day 0) with HLA-A2− HUVECs, after which the non-adherent cells were removed by washing. The cell layers were analysed by three-colour flow cytometry staining for HLA-A2, CD11b and CD105 on (A) Day 1 and (B) Day 2. These plots were gated for HLA-A2+ cells. Forward scatter/side scatter dot plots gated for HLA-A2+ cells on Day 0 (C) and Day 2 (D) was shown. These are representative of 2 individual experiments.
From: Tso C, Rye K-A, Barter P (2012)
Phenotypic and Functional Changes in Blood Monocytes Following Adherence to Endothelium.
PLoS ONE 7(5): e37091.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for flow cytometry.
Image caption:
Increased expression of CD105 and CD144 in the endothelium-adherent monocytes during co-culture. HLA-A2+ PBMCs (1×106 cells/well) were incubated for 2 h (Day 0) with HLA-A2− HUVECs, after which the non-adherent cells were removed by washing. The cell layers were maintained in co-culture up to Day 6, then assessed by dual-colour flow cytometry for HLA-A2 and (A) CD105 and (B) CD144 expression on Day 3 of co-culture. Representative plots from 4–7 individual experiments are shown. The increase in CD105 from Day 0 to Day 6 (C) and CD144 expression from Day 0 to Day 6 (D) is also shown.
From: Tso C, Rye K-A, Barter P (2012)
Phenotypic and Functional Changes in Blood Monocytes Following Adherence to Endothelium.
PLoS ONE 7(5): e37091.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for flow cytometry.
Image caption:
Expression of endothelial antigens in endothelium-adherent monocytes in co-culture with HCAECs. HLA-A2+ PBMCs (1×106 cells/well) were incubated for 2 h (Day 0) with HLA-A2− HCAECs, after which the non-adherent cells were removed by washing. The cell layers were analysed by dual-colour flow cytometry for HLA-A2 and (A) CD105, (B) eNOS and (C) VEGFR2 expression on Day 2 of co-culture.
From: Tso C, Rye K-A, Barter P (2012)
Phenotypic and Functional Changes in Blood Monocytes Following Adherence to Endothelium.
PLoS ONE 7(5): e37091.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for flow cytometry
Image caption:
Immunophenotype of mesenchymal stem cells from human bone marrow. MSC cells were prepared as reported in Materials and Methods. MSCs from passage 2 were harvested and labeled with antibodies against CD105 and CD29 (positive MSCs markers) and CD45, CD34 and CD14 (MSCs negative markers) and analyzed by FACS. Histograms represent the staining of cells with the indicated antibody.
From: Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, et al.
(2011)
The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells.
PLoS ONE 6(12): e28555.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
AlexaFlourA488® conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557A488) used for flow cytometry on human mesenchymal stem cells.
Image caption:
Immunophenotyping of freshly isolated ((c), (d)) and cultured CD105+ hMSCs (d) was evaluated by flow cytometry after staining of specific cell surface markers. Corresponding isotype controls were used as negative controls
From: Anna Schade, Paula Müller, Evgenya Delyagina, et al.
Magnetic Nanoparticle Based Nonviral MicroRNA Delivery into Freshly Isolated CD105+ hMSCs,”
Stem Cells International, vol. 2014, Article ID 197154, 11 pages.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557F) used for flow cytometry on human bone marrow deived mesenchymal stem cells.
Image caption:
Flow cytometric analysis and Wnt profiles of hMSCs by the induction of NTs. (A) Bone marrow-derived hMSCs were analyzed following four cell passages. hMSCs were positive for CD44, CD73, CD105, CD166, and Stro-1, and negative for CD14 and CD34. The solid curves indicate each type of antibody, and the filled curves indicate mouse IgG as the negative control. (B) mRNA levels of MAP2 were quantified on days 7, 14, and 21 during stimulation with NTs. NTs significantly increased MAP2 levels on days 14 and 21. Untreated hMSCs served as the control. (C) mRNA levels of Wnt1, Wnt3a, Wnt5a, Wnt7a, and Wnt7b were quantified on days 7, 14, and 21 during stimulation with NTs. NTs increased the expression of Wnt1 and induced expressions of Wnt7a and Wnt7b. * p<0.05, ** p<0.01 (i.e., treated vs. control in the Wnt1, Wnt3a, and Wnt5a groups; NTs at 14 and 21 days vs. NTs at 7 days in the Wnt7a and Wnt7b groups). Data are presented as the mean ± SD of one triplicate experiment that was representative of three independent experiments. * p<0.05, ** p<0.01 (i.e., treated vs. control). ND, not determined.
From: Tsai H-L, Deng W-P, Lai W-FT, Chiu W-T, Yang C-B, et al. (2014)
Wnts Enhance Neurotrophin-Induced Neuronal Differentiation in Adult Bone-Marrow-Derived Mesenchymal Stem Cells via Canonical and Noncanonical Signaling Pathways.
PLoS ONE 9(8): e104937.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for flow cytometry on brain microvascular endothelial cells
Image caption:
Characterization and functional features of human and murine BMVECs. (A) Phase contrast micrographs of confluent monolayers of human (left image) and murine (right image) BMVECs. BMVECs present the typical “cobblestone appearance”. Scale bar, 100 μm and 200 μm for human BMVECs and murine BMVECs. B) Human (left image) and murine (right image) BMVECs showed a clear cytoplasmic staining for CD31. Scale bar, 50 μm. C) Human (left image) and murine (right image) cells displayed an intense positive immunofluorescence for vWf. Scale bar, 50 μm. D) Flow cytometric analysis of BMVECs. Human BMVECs resulted positive (gray histograms) for CD31 (left graph), CD105, CD146 (left gaph), UEA-1 staining; murine BMVECs resulted positive for CD31 (right graph), CD34, CD146 (right graph) and Tie-2 staining. White histograms represent the isotype controls of each antibody. E) Capillary tube-like structure produced by human (left image) and murine (right image) BMVECs, 7 h after plating onto Matrigel. Scale bar, 100 μm. F) LDL-uptake assay on human (left image) and murine (right image) BMVECs. Scale bar, 50 μm. G) Human (left image) and murine (right image) BMVECs were labelled for GLUT-1. Scale bar, 50 μm. H) Immunofluorescence for eNOS in human (left image) and murine (right image) BMVECs. Scale bar, 50 μm. All nuclei were counterstained with DAPI (blue). One representative of three independent experiments performed in blind is shown for each figure.
From: Navone SE, Marfia G, Nava S, Invernici G, Cristini S, Balbi S, Sangiorgi S, Ciusani E, Bosutti A, Alessandri G, Slevin M, Parati EA.
Human and mouse brain-derived endothelial cells require high levels of growth factors medium for their isolation, in vitro maintenance and survival.
Vasc Cell. 2013 May 14;5(1):10.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557F) used for the evaluation of endoglin expression on mesenchymal stem cells by flow cytometry.
Image caption:
(A) Platinum accumulation in MSC and TGCT cell lines upon 24h treatment with 3 μM cisplatin and analyzed by atomic absorption spectroscopy. Mean ± standard deviation; MSC n = 8, TGCT both n = 3; * p<0.05 vs MSC. (B) Cell cycle populations from analyses as shown in Fig 1C (propidium iodide staining). Data are presented as% of cells distributed to cell cycle phases as mean ± standard deviation; n≥4; * p<0.05, *** p<0.001 vs. control. (C) MSC after subapoptotic damage by cisplatin upon reconstitution of proliferation were analyzed for surface antigen expression by flow cytometry. Data are shown as histograms of fluorescence. Isotype controls (no filling) are overlaid on specific FITC- or PE-conjugated antibodies. Data are representative of at least 4 independent experiments. (D) MSC from (C) were incubated in growth medium (u) or specific osteogenic (o) and adipogenic (a) differentiation media. Cells were stained with alizarin pH4 and oil red for calcium deposition and lipid droplets, respectively. Data are representative of at least 4 independent experiments. Light microscopy, scale bar– 100μm.
From: Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll H-J, Müller-Tidow C, et al. (2017)
Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest.
PLoS ONE 12(1): e0169921.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557F) used for the evaluation of endoglin expression on mesenchymal stem cells by flow cytometry.
Image caption:
(A) MSC cultured for up to 14 days under physioxia or hypoxia were analyzed for surface antigen expression by flow cytometry. Data are representative of at least 3 independent experiments. (B) MSC from (A) were incubated in growth medium (u) or specific osteogenic (o) and adipogenic (a) differentiation media. Cells were stained with alizarin pH4 and oil red for calcium deposition and lipid droplets, respectively. Data are representative of 3 independent experiments. Light microscopy, scale bar– 100 μm. (C) Growth kinetics of MSC under normoxic, physioxic and hypoxic conditions. Cultivation under physioxia/hypoxia started on day 0. An aliquot of hypoxic cells was reoxygenated to normoxic conditions on d15. Data are representative of 5 independent experiments. (D) Cell cycle analyses of normoxic and hypoxic MSC were performed upon pyronin/7-AAD staining. Data are presented as% of cells in cell cycle phase as mean—standard deviation; n = 5.
From: Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll H-J, Müller-Tidow C, et al. (2017)
Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest.
PLoS ONE 12(1): e0169921.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557F) used for the evaluation of endoglin expression on mesenchymal stem cells by flow cytometry.
Image caption:
(A) Growth kinetic was performed with MSC with lentiviral p53 knock down (MSCp53kd), MSC with lentiviral control sh-RNA (ctr-MSC) and wildtype MSC (wt-MSC) from the same donor. Lentiviral transduction was performed on day 0. Data are representative of 4 independent experiments. (B) Late passage MSCp53kd were stained for senescence-associated beta-galactosidase activity. Data are representative of 2 independent experiments. Light microscopy, scale bar– 200 μm. (C) MSCp53kd were analyzed for surface antigen expression by flow cytometry. Data are shown as histograms of fluorescence. Isotype controls (no filling) are overlaid on specific FITC- or PE-conjugated antibodies. Data are representative of 4 independent experiments. (D) MSCp53kd were incubated in growth medium (u) or specific osteogenic (o) and adipogenic (a) differentiation media. Cells were stained with alizarin pH4 and oil red for calcium deposition and lipid droplets, respectively. Data are representative of 4 independent experiments. Light microscopy, scale bar– 200 μm. (E) MSCp53kd were treated 72 h with cisplatin under normoxic, physioxic and hypoxic conditions and analyzed for cell cycle distribution. Data are presented as% of cells in cell cycle phase as mean—standard deviation; n = 3. (F) Whole protein lysates from the experiment shown in (E) were analyzed by western blot. Data are representative of 3 independent experiments.
From: Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll H-J, Müller-Tidow C, et al. (2017)
Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest.
PLoS ONE 12(1): e0169921.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for the identification of mesenchymal stem cells in mixed bone marrow cell populations by flow cytometry.
Image caption:
MSCs used in this study were characterized for marker expression by flow cytometric analysis. Dashed histograms indicate staining with isotype-matched control antibody and solid histograms denote the specific expression of each indicated marker.
From: Lee HJ, Kim SN, Jeon MS, Yi T, Song SU.
ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells.
Sci Rep. 2017 Mar 14;7:44486.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for the evaluation of endoglin expression on human adipose derived stem cells by flow cytometry.
Image caption:
Analysis of hASC markers.
(A) CD90. (B) CD105. (C) Nanog. (D) Sox-2. (E) STRO-1. (F) CD45RO. (G) CD117. (H) Quantification of expression of positive and negative markers. Graphs show the expression of different markers in hASCs. The expression of the markers was assessed using flow cytometry by means of the intensity of the emitted fluorescence (FL1 and FL2). The expression of the positive markers, CD90, CD105, and STRO-1 (surface markers mesenchymal) and Nanog and Sox-2 (pluripotency markers) is compared to the decreased expression of negative markers (CD45RO and CD117). Data are represented as mean ± standard deviation. The statistical analyses were obtained using an ANOVA followed by Dunnett's test with P <0.05 being considered significant.
From: Olimpio RMC, de Oliveira M, De Sibio MT, Moretto FCF, Deprá IC, Mathias LS, et al. (2018)
Cell viability assessed in a reproducible model of human osteoblasts derived from human adipose-derived stem cells.
PLoS ONE 13(4): e0194847.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Phycoerythrin conjugated Mouse anti Human CD90 antibody, clone AD2 (MCA1557PE) used to evaluate CD90 expression on bone-marrow derived mesenchymal stem cells by flow cytometry
Image caption:
Chaturvedi CP, Tripathy NK, Minocha E, Sharma A, Rahman K, Nityanand S.
Altered Expression of Hematopoiesis Regulatory Molecules in Lipopolysaccharide-Induced Bone Marrow Mesenchymal Stem Cells of Patients with Aplastic Anemia. Stem Cells Int. 2018 Oct 17;2018:6901761.
From: Insert article citation with space after colon and Hyperlink to PubMed record.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used for the evaluation of CD105 expression on dental pulp derived cells by flow cytometry.
Image caption:
Cell surface markers. (a) Cell surface markers before separation into sparse (sDPSCs) and dense (dDPSCs) groups. A representative case among seven donors is shown. (b) MSC marker expression in sparse (sDPSCs) and dense (dDPSCs) groups. **p = 0.0079 and ***p = 0.0006 (Mann-Whitney U test). The error bar is SD (n = 7). Solid colored histograms represent IgGκ treated cells for control, and open colored histograms represent fluorophore labeled antibody treated cells.
From: Noda S, Kawashima N, Yamamoto M, Hashimoto K, Nara K, Sekiya I, Okiji T.
Effect of cell culture density on dental pulp-derived mesenchymal stem cells with reference to osteogenic differentiation.
Sci Rep. 2019 Apr 1;9(1):5430.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD105 antibody, clone SN6 (MCA1557) used to assess endoglin expression on cells isolated from human umbilical cord by flow cytometry.
Image caption:
Morphology and identification of the hucMSC and hucMSC-Exos.
Flow cytometry was used to detect immunophenotype.
From: Huang Q, Gong M, Tan T, Lin Y, Bao Y, Fan C.
Human Umbilical Cord Mesenchymal Stem Cells-Derived Exosomal MicroRNA-18b-3p Inhibits the Occurrence of Preeclampsia by Targeting LEP.
Nanoscale Res Lett. 2021 Feb 10;16 (1): 27.
doi: 10.1186/s11671-021-03475-5.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Alexa Fluor 488 conjugated Rat anti Mouse CD68 antibody, clone FA-11 (MCA1957A488) used to label macrophages in murine muscle segments by immunofluorescence.
Image caption:
Alteration of macrophage polarization in the perivascular bed of growing collateral vessels after pharmacological stimulation with IL10 and anti-IL10.
(a) Confocal micrographs of macrophage differentiation subtypes 3 d and 7 d after FAL. Sections of adductor muscles segments containing growing collateral vessels (V) were stained using DAPI and macrophage differentiation markers CD68 and CD163. The ratio of the alternatively (CD163+/CD68+) activated phenotype, indicated by white arrows, and classically (CD163-/CD68+) activated phenotype varies with indicated application. Scale bar: 25μm.
From: Götze AM, Schubert C, Jung G, Dörr O, Liebetrau C, Hamm CW, Schmitz-Rixen T, Troidl C, Troidl K.
IL10 Alters Peri-Collateral Macrophage Polarization and Hind-Limb Reperfusion in Mice after Femoral Artery Ligation.
Int J Mol Sci. 2020 Apr 17;21(8):2821.
doi: 10.3390/ijms21082821.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Alexa Fluor 647 conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557A647) used to evaluate levels of CD105 expression on peripheral blood (PB) and bone marrow aspirate (BMA) samples by flow cytometry.
Image caption:
Flow cytometry analysis of MSC-like cells from PB and BMA.
The proportion of CD34−/CD29+/CD105+-nucleated cells in the PB was significantly lower than that in the BMA (t test, p <0.01, n = 4).
From: Niu CC, Lin SS, Yuan LJ, Chen LH, Pan TL, Yang CY, Lai PL, Chen WJ.
Identification of mesenchymal stem cells and osteogenic factors in bone marrow aspirate and peripheral blood for spinal fusion by flow cytometry and proteomic analysis.
J Orthop Surg Res. 2014 May 3;9:32.
doi: 10.1186/1749-799X-9-32.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD105 antibody, clone SN6 (MCA1557F) used to evaluate expression of mesenchymal stem cell markers in vitro by flow cytometry.
Image caption:
In culture, MSCs presented a spindle-shaped and fibroblast-like morphology. Various cell surface markers were analyzed by flow cytometry; positive results were obtained for CD73, CD90, and CD105 (MSC markers), whereas negative results were obtained for CD34 and CD45 (hematopoietic markers).
From: Supokawej A, Kheolamai P, Nartprayut K, U-Pratya Y, Manochantr S, Chayosumrit M, Issaragrisil S.
Cardiogenic and myogenic gene expression in mesenchymal stem cells after 5-azacytidine treatment.
Turk J Haematol. 2013 Jun;30(2):115-21.
doi: 10.4274/Tjh.2012.0161.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Human CD105:Alexa Fluor® 488
Mouse anti Human CD105:Alexa Fluor® 647
Mouse anti Human CD105:FITC
Mouse anti Human CD105
Mouse anti Human CD105:RPE
Mouse anti Human CD105:RPE-Alexa Fluor® 647
Mouse anti Human CD105:StarBright Blue 700
Mouse anti Human CD105:StarBright Violet 440
Mouse anti Human CD105:StarBright Violet 515
Mouse anti Human CD105:StarBright Violet 610
Mouse anti Human CD105:StarBright Violet 670
Mouse anti Human CD105:StarBright Violet 570
Mouse anti Human CD105:StarBright Violet 710
Mouse anti Human CD105:StarBright Violet 790
- Product Type
- Monoclonal Antibody
- Clone
- SN6
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA1557A488T | F | 25 Tests/0.25ml |
|
|
| MCA1557A488 | F | 100 Tests/1ml |
|
|
| MCA1557A647 | F | 100 Tests/1ml |
|
|
| MCA1557A647T | F | 25 Tests/0.25ml |
|
|
| MCA1557F | F | 0.1 mg |
|
|
| MCA1557FT | F | 25 µg |
|
|
| MCA1557T | C* F IP WB | 25 µg |
|
|
| MCA1557 | C* F IP WB | 0.2 mg |
|
|
| MCA1557PE | F | 100 Tests |
|
|
| MCA1557PET | F | 25 Tests |
|
|
| MCA1557P647 | F | 100 Tests |
|
|
| MCA1557SBB700 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV440 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV515 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV610 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV670 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV570 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV710 | F | 100 Tests/0.5ml |
|
|
| MCA1557SBV790 | F | 100 Tests/0.5ml |
|
Mouse anti Human CD105 antibody, clone SN6 recognizes the human endoglin, also known as CD105. CD105 is a glycoprotein homodimer of ~95 kDa subunits expressed by endothelial cells, activated monocytes and some leukemia cells.
Product Details
- Target Species
- Human
- Species Cross-Reactivity
-
Target Species Cross Reactivity Horse Cynomolgus monkey Rhesus Monkey Primate Expected from Sequence - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647- liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to RPE-Alexa Fluor 647 - lyophilized
- Product Form
- Purified IgG conjugated to StarBright Blue 700 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 440 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 515 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 610 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 670 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 570 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 710 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 790 - liquid
- Reconstitution
- Pack Size: 100 TestsReconstitute with 1ml distilled waterPack Size: 25 TestsReconstitute with 0.25 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Carrier Free
- Yes
- Immunogen
- Partially purified cell membrane antigens from fresh leukemia cells
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse P3/NS1/1-Ag4-1 myeloma cell line
Storage Information
- Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. - Storage
- Pack Size: 100 TestsPrior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.Pack Size: 25 TestsStore at +4oC. DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P17813
- Entrez Gene
- ENG
- GO Terms
- GO:0001300 chronological cell aging
- GO:0001569 patterning of blood vessels
- GO:0001937 negative regulation of endothelial cell proliferation
- GO:0001947 heart looping
- GO:0003084 positive regulation of systemic arterial blood pressure
- GO:0007155 cell adhesion
- GO:0004888 transmembrane receptor activity
- GO:0005024 transforming growth factor beta receptor activity
- GO:0005072 transforming growth factor beta receptor, cytoplasmic mediator activity
- GO:0005114 type II transforming growth factor beta receptor binding
- GO:0005534 galactose binding
- GO:0005539 glycosaminoglycan binding
- GO:0005615 extracellular space
- GO:0005624 membrane fraction
- GO:0007179 transforming growth factor beta receptor signaling pathway
- GO:0050431 transforming growth factor beta binding
- GO:0009897 external side of plasma membrane
- GO:0009986 cell surface
- GO:0010552 positive regulation of gene-specific transcription from RNA polymerase II promoter
- GO:0010553 negative regulation of gene-specific transcription from RNA polymerase II promoter
- GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation
- GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
- GO:0022009 central nervous system vasculogenesis
- GO:0022617 extracellular matrix disassembly
- GO:0030155 regulation of cell adhesion
- GO:0030509 BMP signaling pathway
- GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
- GO:0030513 positive regulation of BMP signaling pathway
- GO:0031953 negative regulation of protein autophosphorylation
- GO:0034713 type I transforming growth factor beta receptor binding
- GO:0042060 wound healing
- GO:0042127 regulation of cell proliferation
- GO:0042803 protein homodimerization activity
- GO:0045449 regulation of transcription
- GO:0048185 activin binding
- GO:0048745 smooth muscle tissue development
- GO:0048844 artery morphogenesis
- GO:0048845 venous blood vessel morphogenesis
- GO:0051001 negative regulation of nitric-oxide synthase activity
- GO:0060326 cell chemotaxis
- GO:0060394 negative regulation of pathway-restricted SMAD protein phosphorylation
- GO:0070022 transforming growth factor beta receptor complex
- GO:0070483 detection of hypoxia
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Regulatory
- For research purposes only
Applications of CD105 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | 1/10 Pack Size: 100 Tests/1ml 1/5 Pack Size: 25 Tests/0.25ml |
|
| Flow Cytometry | Neat | ||
| Flow Cytometry | 1/10 | 1/50 | |
| Immunohistology - Frozen 1 | |||
| Immunohistology - Paraffin | |||
| Immunoprecipitation | |||
| Western Blotting | |||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat |
- 1The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
Copyright © 2021 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG1 Negative Control:Alexa Fluor® 488 | MCA928A488 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:Alexa Fluor® 647 | MCA928A647 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:FITC | MCA928F | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control | MCA928 | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control:RPE | MCA928PE | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control:RPE-Alexa Fluor® 647 | MCA928P647 | F | 100 Tests/1ml |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test |
Product Specific References
Source Reference
-
Haruta, Y. & Seon, B.K. (1986) Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.
Proc Natl Acad Sci USA 83 (20): 7898-902.
References for CD105 antibody
-
Hauser, P.V. et al. (2010) Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery.
Am J Pathol. 177: 2011-21. -
Jin, H.J. et al. (2010) GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells.
Cell Mol Life Sci. 67 (11): 1845-58. -
Nagano, M. et al. (2007) Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood.
Blood 110 (1): 151-60. -
Braun, J. et al. (2010) Evaluation of the osteogenic and chondrogenic differentiation capacities of equine adipose tissue-derived mesenchymal stem cells.
Am J Vet Res. 71 (10): 1228-36. -
Diaz-Romero, J. et al. (2008) Immunophenotypic changes of human articular chondrocytes during monolayer culture reflect bona fide dedifferentiation rather than amplification of progenitor cells.
J Cell Physiol. 214: 75-83. -
Agha-Hosseini, F. et al. (2010) In vitro isolation of stem cells derived from human dental pulp.
Clin Transplant. 24: E23-8. -
Arufe, M.C. et al. (2010) Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes.
J Cell Biochem. 111: 834-45. -
Balmayor, E.R. et al. (2011) Synthesis and functionalization of superparamagnetic poly-ε-caprolactone microparticles for the selective isolation of subpopulations of human adipose-derived stem cells.
J R Soc Interface 8: 896-908. -
Benetti, A. et al. (2008) Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
Cancer Res. 68: 8626-34. -
Ciccocioppo, R. et al. (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease.
Gut 60: 788-98. -
Cox, G. et al. (2011) The use of the reamer-irrigator-aspirator to harvest mesenchymal stem cells.
J Bone Joint Surg Br. 93: 517-24. -
Ferro, F. et al. (2010) Biochemical and biophysical analyses of tissue-engineered bone obtained from three-dimensional culture of a subset of bone marrow mesenchymal stem cells.
Tissue Eng Part A 16: 3657-67. -
Lozanoska-Ochser, B. et al. (2008) Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration.
J Immunol. 181: 6109-16. -
Sallustio, F. et al. (2010) TLR2 plays a role in the activation of human resident renal stem/progenitor cells.
FASEB J. 24: 514-25. -
Tso, C. et al. (2012) Phenotypic and functional changes in blood monocytes following adherence to endothelium.
PLoS One 7: e37091. -
Hu, N. et al. (2013) Long-term outcome of the repair of 50 mm long median nerve defects in rhesus monkeys with marrow mesenchymal stem cells-containing, chitosan-based tissue engineered nerve grafts.
Biomaterials 34: 100-11. -
Cho, H.J. et al. (2013) Generation of human secondary cardiospheres as a potent cell processing strategy for cell-based cardiac repair.
Biomaterials 34: 651-61. -
Kang, S.D. et al. (2013) Isolation of Functional Human Endothelial Cells from Small Volumes of Umbilical Cord Blood.
Ann Biomed Eng. 41: 2181-92. -
Mehrkens, A. et al. (2013) Non-adherent mesenchymal progenitors from adipose tissue stromal vascular fraction.
Tissue Eng Part A 20: 1081-8. -
De Schauwer, C. et al. (2012) In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry.
Cytometry A 81: 312-23. -
Zhang, J. et al. (2016) Bone mesenchymal stem cells differentiate into myofibroblasts in the tumor microenvironment.
Oncol Lett. 12 (1): 644-50. -
Morsing, M. et al. (2016) Evidence of two distinct functionally specialized fibroblast lineages in breast stroma.
Breast Cancer Res. 18 (1): 108. -
Williamson, K.A. et al. (2015) Restricted differentiation potential of progenitor cell populations obtained from the equine superficial digital flexor tendon (SDFT).
J Orthop Res. 33 (6): 849-58. -
Lützkendorf, J. et al. (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest.
PLoS One. 12 (1): e0169921. -
Lee, H.J. et al. (2017) ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cells.
Sci Rep. 7: 44486. -
Yi, T. et al. (2015) Manufacture of Clinical-Grade Human Clonal Mesenchymal Stem Cell Products from Single Colony Forming Unit-Derived Colonies Based on the Subfractionation Culturing Method.
Tissue Eng Part C Methods. 21 (12): 1251-62. -
Boccardo, S. et al. (2016) Engineered mesenchymal cell-based patches as controlled VEGF delivery systems to induce extrinsic angiogenesis.
Acta Biomater. 42: 127-35. -
Mumaw, J.L. et al. (2015) Feline mesenchymal stem cells and supernatant inhibit reactive oxygen species production in cultured feline neutrophils.
Res Vet Sci. 103: 60-9. -
Bertolo, A. et al. (2017) Oxidative status predicts quality in human mesenchymal stem cells.
Stem Cell Res Ther. 8 (1): 3. -
GarikipatiV, N.S. et al. (2018) Isolation and characterization of mesenchymal stem cells from human fetus heart.
PLoS One. 13 (2): e0192244. -
Olimpio, R.M.C. et al. (2018) Cell viability assessed in a reproducible model of human osteoblasts derived from human adipose-derived stem cells.
PLoS One. 13 (4): e0194847. -
Lotfi, R. et al. (2018) ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase.
Immun Inflamm Dis. Oct 10 [Epub ahead of print]. -
Santos,V.H.D. et al. (2019) Evaluation of alginate hydrogel encapsulated mesenchymal stem cell migration in horses.
Res Vet Sci. 124: 38-45. -
Noda, S. et al. (2019) Effect of cell culture density on dental pulp-derived mesenchymal stem cells with reference to osteogenic differentiation.
Sci Rep. 9 (1): 5430. -
Manini, I. et al. (2020) Heterogeneity Matters: Different Regions of Glioblastoma Are Characterized by Distinctive Tumor-Supporting Pathways.
Cancers (Basel). 12 (10) Oct 13 [Epub ahead of print]. -
Cargnoni, A. et al. (2020) Amniotic MSCs reduce pulmonary fibrosis by hampering lung B-cell recruitment, retention, and maturation.
Stem Cells Transl Med. 9 (9): 1023-35. -
Huang, Q. et al. (2021) Human Umbilical Cord Mesenchymal Stem Cells-Derived Exosomal MicroRNA-18b-3p Inhibits the Occurrence of Preeclampsia by Targeting LEP.
Nanoscale Res Lett. 16 (1): 27. -
Piñeiro-Ramil, M. et al. (2020) Immortalizing Mesenchymal Stromal Cells from Aged Donors While Keeping Their Essential Features.
Stem Cells Int. 2020: 5726947. -
Kim, M. et al. (2020) A Small-Sized Population of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Shows High Stemness Properties and Therapeutic Benefit.
Stem Cells Int. 2020: 5924983. -
Niu, C.C. et al. (2014) Identification of mesenchymal stem cells and osteogenic factors in bone marrow aspirate and peripheral blood for spinal fusion by flow cytometry and proteomic analysis.
J Orthop Surg Res. 9: 32. -
Supokawej, A. et al. (2013) Cardiogenic and myogenic gene expression in mesenchymal stem cells after 5-azacytidine treatment.
Turk J Haematol. 30 (2): 115-21.
Further Reading
-
Burk, J. et al. (2013) Equine cellular therapy--from stall to bench to bedside?
Cytometry A 83 (1): 103-13. -
Carrade, D.D. et al. (2012) Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells.
Cell Med. 4: 1-11.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
Our CD105 (SN6) Antibody has been referenced in >73 publications*
*Based on June 2020 data from CiteAb's antibody search engine.
